职称：讲师
邮箱：lupingpang@zzu.edu.cn
地址：郑州大学省部共建食管癌防治国家重点实验室201室
个人简介
2013年获郑州大学理学学士学位；2016年获郑州大学医学硕士学位。2020年9月获比利时鲁汶大学生物医学博士学位，期间从事氨酰-tRNA合成酶的结构、功能及催化机制研究与小分子抑制剂研发。2020年9月至2021年8月，继续在鲁汶大学从事博士后研究。2021年10月入职郑州大学医学科学院。
主要研究方向
综合运用分子生物学、生物化学、物理化学和结构生物学等手段，研究肿瘤及代谢性疾病相关重要蛋白的结构、功能、作用机制，并基于靶蛋白结构开展小分子抑制剂/激动剂的研发。
代表性成果
1 Song, M.; Pang, L.; Zhang, M.; Qu, Y.; Laster, K. V.; Dong, Z. Cdc2-like Kinases: Structure, Biological Function, and Therapeutic Targets for Diseases. Signal Transduct Target Ther 2023, 8 (1), 148.
2 Pang, L.#; Lenders, S.#; Osipov, E. M.; Weeks, S. D.; Rozenski, J.; Piller, T.; Cappoen, D.; Strelkov, S. V.; Van Aerschot, A. Structural basis of cysteine ligase MshC inhibition by cysteinyl-sulfonamides. Int J Mol Sci 2022, 23 (23), 15095. (#Co-first authors)
3 Pang, L.; Zanki, V.; Strelkov, S. V.; Van Aerschot, A.; Gruic-Sovulj, I.; Weeks, S. D. Partitioning of the initial catalytic steps of leucyl-tRNA synthetase is driven by an active site peptide-plane flip. Commun Biol 2022, 5 (1), 883.
4 Shen, D.; Wang, B.; Gao, Y.; Zhao, L.; Bi, Y.; Zhang, J.; Wang, N.; Kang, H.; Pang, J.; Liu, Y.; Pang, L.; Chen, Z.-S.; Zheng, Y.-C.; Liu, H.-M. Detailed resume of RNA m6A demethylases. Acta Pharm Sin B 2022, 12 (5), 2193–2205.
5 Pang, L.; Weeks, S. D.; Juhás, M.; Strelkov, S. V.; Zitko, J.; Van Aerschot, A. Towards novel 3-aminopyrazinamide-based prolyl-tRNA synthetase inhibitors: in silico modelling, thermal shift assay and structural studies. Int J Mol Sci 2021, 22 (15), 7793.
6 Pang, L.; Weeks, S. D.; Van Aerschot, A. Aminoacyl-tRNA synthetases as valuable targets for antimicrobial drug discovery. Int J Mol Sci 2021, 22 (4), 1750.
7 Pang, L.#; Nautiyal, M.#; De Graef, S.; Gadakh, B.; Zorzini, V.; Economou, A.; Strelkov, S. V.; Van Aerschot, A.; Weeks, S. D. Structural insights into the binding of natural pyrimidine-based inhibitors of class II aminoacyl-tRNA synthetases. ACS Chem. Biol. 2020, 15 (2), 407–415. Highlighted by the editor (#Co-first authors)
8 De Ruysscher, D.#; Pang, L.#; Lenders, S. M. G.; Cappoen, D.; Cos, P.; Rozenski, J.; Strelkov, S. V.; Weeks, S. D.; Van Aerschot, A. Synthesis and structure-activity studies of novel anhydrohexitol-based leucyl-tRNA synthetase inhibitors. Eur. J. Med. Chem. 2021, 211, 113021. (#Co-first authors)
9 Zhang, B.#; Pang, L.#; Nautiyal, M.; De Graef, S.; Gadakh, B.; Lescrinier, E.; Rozenski, J.; Strelkov, S. V.; Weeks, S. D.; Van Aerschot, A. Synthesis and biological evaluation of 1,3-dideazapurine-like 7-amino-5-hydroxymethyl-benzimidazole ribonucleoside analogues as aminoacyl-tRNA synthetase inhibitors. Molecules 2020, 25 (20), 4751. (#Co-first authors)
10 Wang, B.#; Zhao, B.#; Pang, L.#; Zhao, Y.-D.; Guo, Q.; Wang, J.-W.; Zheng, Y.-C.; Zhang, X.-H.; Liu, Y.; Liu, G.-Y.; Guo, W.-G.; Wang, C.; Li, Z.-H.; Mao, X.-J.; Yu, B.; Ma, L.-Y.; Liu, H.-M. LPE-1, an orally active pyrimidine derivative, inhibits growth and mobility of human esophageal cancers by targeting LSD1. Pharmacol Res 2017, 122, 66–77. (#Co-first authors)
